23 November 2015 - CVS Health announced today that Repatha (evolocumab) from Amgen Inc. will be added as the only PCSK9 inhibitor on the CVS/caremark commercial formularies.

For more details, go to: https://www.cvshealth.com/content/cvs-health-announces-formulary-and-therapy-strategy-pcsk9-inhibitors